Compare UiPath Inc (PATH) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Sanofi SA — how do they compare? UiPath Inc trades at $13.47 (market cap $6.91B), while Sanofi SA trades at $40.11 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 13.8× UiPath Inc's market cap, and Sanofi SA pays a 6.01% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Sanofi SA for 94 Days on average.
| PATH | SNY | |
|---|---|---|
Market Cap | $6.91B | $95.18B |
Volume | 34,321,250 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $19.29 | $52.34 |
52-Week Low | $9.38 | $39.51 |
Typical Hold Time | 139 Days | 94 Days |
Enterprise Value | $5.70B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.45, up 2.87% today, showing technical bullish momentum despite mixed earnings. The company demonstrates strong revenue growth from $1.43B in 2025 to projected $1.7B in 2026, with net income turning positive at $362M. Recent partnerships with Snowflake and BDO highlight strategic expansion in AI orchestration, while analyst consensus remains cautious with 67% hold ratings.
PATH offers growth potential through AI automation leadership but faces execution risks amid competitive pressures. The stock trades below consensus target of $15.13, suggesting 12% upside if guidance is met. Key risks include pricing pressure and integration challenges with new partnerships.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
